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The 1H-Imidazo-[4,5-c]quinolines are a class of compounds that are agonists towards Toll-like 
receptor 7 and 8 (TLR7/8). For example, Imiquimod and Resiquimod have been shown to act as 
vaccine adjuvants, enhancing antigen-specific antibody production and skewing the immunity 
towards a Th1 response. Activation of TLR7/8 have been shown to stimulate dendritic cells to 
secrete cytokines, upregulate costimulatory molecule expression and enhance antigen 
presentation to T cells. Imidazoquinoline compounds have demonstrated vaccine adjuvant 
properties in several animal models. The adjuvant effects can be enhanced by measures that 
localize the drug with the vaccine without quickly entering the systemic circulation. Clinical studies 
demonstrate that local immune activation is useful; imiquimod is approved for the topical 
treatment of basal cell carcinomas. However, injection or oral routes of administration of 
imidazoquinolines are not therapeutically beneficial and possibly dangerous due to systemic and 
non-specific activation of the immune system. To take advantage of the adjuvant property of 
imidazoquinolines, they need to be formulated or designed to allow for local immune activation 
without induction of systemic cytokines. This study focuses on developing a new site on the phenyl 
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Chapter 1.1 Immunity  
The immune system is a complex defense mechanism capable of differentiating and destroying 
harmful pathogens while causing minimal damage to the host. In all vertebrates, including 
humans, the immune system is classified into two separate subsystems, the innate and the 
adaptive. The innate immune system, the most primitive, is the first line of defense against harmful 
pathogens, it is nonspecific, rapidly activated, and without memory. Without specific memory, the 
innate immune system needs a way to recognize these pathogens. The innate immune system 
relies on germline-encoded pattern recognition receptors (PRRs) which consist of membrane-
bound and unbound intracellular receptors that serve as guards of the host’s immune system. 
These PRRs identify highly conserved pathogenic fragments referred to as pathogen-associated 
molecular patterns (PAMPs) commonly consisting of antigens commonly found from microbes 
and viruses, such as flagellin or specific RNA/DNA sequences. When a PAMP binds and activates 
a PRR this causes a proinflammatory response of cytokines and interferons (IFN). This response 
is critical for innate and adaptive immune responses. The innate immune system also acts to help 
stimulate the adaptive immune system allowing for long term protection. It is this specific memory 
of pathogens that builds the foundation for vaccination.  
Chapter 1.2 Vaccines and Vaccine Adjuvants 
Vaccines are our greatest defense in preventing infectious diseases.1,2 Vaccines aid in significant 
functions within the healthcare setting. First, they are used as a prophylactic to protect healthy 
individuals, including those who do not have fully competent immune systems from diseases. 
Second, they protect those who are unable to receive vaccinations through the process of “herd 
immunity”. Herd immunity is achieved when a majority of the population, usually between 75-94%, 
depending on the pathogen, have immunity and prevent colonization of the pathogen within the 
population.3 And finally, vaccines can be therapeutic in already established disease, such as the 
Provenge® vaccine in hormone-resistant prostate cancer.4,5 
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The practice of vaccination was reported and widely accepted by Edward Jenner in 1798 when 
he inoculated an 8-year-old boy, James Phipps, with pus derived from a cowpox lesions from a 
milkmaid’s hand. Edward then tried to infect James with the smallpox virus twice, but he was 
ultimately protected from the virus. Since the invention of vaccines, the global market of vaccines 
as of 2015 represent a 32.5 billion dollar market covering over 25 diseases. The market in 2024 
is predicted to grow to 77.5 billion dollars according to Grand View Research, Inc.6 With this 
increase in wealth, there will be a demand to develop vaccinations for unexplored diseases (such 
as malaria, HIV, flaviviruses, and cytomegaloviruses), as well as improve existing vaccines (such 
as the annual influenza, acellular pertussis, and  tuberculosis) that remain suboptimal.7,8 
Chapter 1.2.1 Live Attenuated and Inactivated Vaccines 
The first vaccines were initially derived from whole inactivated or live attenuated pathogens. The 
smallpox and polio vaccines are perhaps the most recognizable and successful vaccines 
developed. The smallpox vaccine that Jenner had developed started from cowpox but more 
recently the vaccine was made from the vaccinia virus of the poxvirus family.9 However, the polio 
vaccine has utilized both strategies of live attenuated oral poliovirus vaccine and the inactivated 
parenteral poliovirus vaccine.10 The oral poliovirus vaccine contains all three serotypes of 
poliovirus that have been attenuated by serial passage though African green monkey kidney cells 
significantly reducing polio’s pathogenicity.11 This vaccine is widely used in the developing world 
due to low cost of manufacturing, ease of oral administration, and the strong induction of humoral 
and mucosal immunity. Most industrialized countries, including the United States, have adopted 
the inactivated parenteral poliovirus vaccine, using formalin to inactivate all three poliovirus 
serotypes. While the inactivated poliovirus vaccine is significantly safer than the attenuated 
vaccine, the inactivated vaccine does suffer from reduced efficacy at eliciting protective immunity 
in the lower intestinal tract, relative to the attenuated vaccine, and does not prevent intestinal 
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shedding of the virus. The inactivated vaccines do however provide protection equal to that of the 
oral vaccine in pharyngeal membranes.12 
Chapter 1.2.2 Subunit Vaccines and Adjuvants 
The tradeoffs between safety and efficacy between live attenuated and inactivated vaccines are 
relevant to many other diseases. Current trends in vaccine development have focused on use of 
highly purified protein antigens, called subunit vaccines. Some examples include Hepatitis B, 
Haemophilus influenza type B, human papillomavirus, and pertussis vaccines. Although subunit 
vaccines are extremely safe, the antigens are frequently poorly immunogenic and rely heavily on 
adjuvants to stimulate immunogenicity and direct adaptive immune responses to the antigen.13,14 
Adjuvants according to Janeway are “immunologists’ dirty little secret” and their role in subunit 
vaccines are essential.15 However, the FDA has only approved a few adjuvants, including AS03, 
AS04, MF59, and aluminum salts. The most commonly used adjuvants are aluminum salts 
commonly referred to as alum.13 The adjuvantic activity of the aluminum salts were described in 
1926 by Glenny et al.. In this work they suggested that an antigen alone was too rapidly eliminated 
to induce robust immune responses, thus the antigens required precipitation with alum in order to 
slow the rate of elimination of the antigen.16 Many groups have expanded the understanding of 
the mechanisms of action of aluminum salts. Summarily, it has been observed that alum increases 
antigen uptake by dendritic cells (DCs) which leads to the recruitment of leukocytes to the injection 
site, indirectly activating the innate immune system by inducing necrosis and causing the release 
of uric acid, a danger signal.17 Studies have been performed to see if alum has a receptor but 
nothing has been uncovered.18,19  
While alum-adjuvanted vaccines are generally safe and well tolerated with over one billion doses 
administered world-wide, they are not without limitations.20 Aluminum salt-adjuvanted vaccines 
are Th2 polarizing, providing limited benefit in vaccines targeting intracellular pathogens that rely 
on either Th1 or Th17 immunity. This was emphasized by Warfel et. al. in comparing the whole-
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cell pertussis vaccine to the alum adjuvanted acellular pertussis vaccine.21 Warfel et. al. 
demonstrate that baboons vaccinated with acellular, alum adjuvanted Infanrix® 
(GlaxoSmithKline) were able to prevent major disease upon challenge with B. pertussis in a 
similar manner to the whole-cell vaccine, but failed to prevent either colonization of the bacterium 
or transmission to naïve animals. They also noted that both natural infections and vaccinations 
with the whole-cell vaccine resulted in memory Th1 and Th17 cells, while the acellular vaccine 
yielded Th1 and Th2 responses. Thus, the acellular pertussis vaccine was able to protect animals 
from major disease, but it showed potential limitations in enabling “herd immunity”.21 
In addition to alum, the FDA has approved AS04 as a vaccine adjuvant. AS04 is a Th1-polarizing 
immune stimulator approved in use against human papilloma virus types 16 and 18. This builds 
upon the adjuvantic activity of alum immunogenicity through the adsorption of the TLR4 agonist 
monophosphoryl lipid A (MPLA) to alum.22,23 Didierlaurent et. al. demonstrated that the activity of 
AS04 was driven primarily by the TLR4 component and resulted in enhancement of DC and 
monocyte antigen uptake and cytokine secretion both at the site of injection and draining lymph 
node. The alum component of AS04, on the other hand, served to prolong the APC stimulation 
observed at the injection site.23 They also demonstrated that AS04 does not directly stimulate T 
cells through either CD69 upregulation or IFN-γ secretion, but only appeared to drive APC 
activation with strong expression of TNF-α, IL-6, and IL-1β.23   
The latest generation of adjuvants to gain FDA approval are the oil-in-water emulsions MF59, 
squalene in water,24 and AS03, squalene and α-tocopherol in water. The AS03 adjuvant is made 
up of the oily compounds, D,L-alpha-tocopherol (vitamin E) and squalene, and an emulsifier, 
polysorbate 80, and water containing some salts.25 Early work on establishing mechanisms of 
action for these adjuvants proved that neither of the systems worked through the formation of 
micro-depots, but rather through leukocyte recruitment to the site of injection and the draining 
lymph nodes.26,27 The oil-in-water emulsions differ from many TLR agonists, such as MPLA in 
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AS04, in that they act by inducing the release of chemokines in APCs, which increase the number 
of leukocytes that migrate to the site of injection and increase antigen internalization. However, 
they do not induce strong co-stimulatory molecule upregulation in APCs or activate T cells 
directly.25,28,29 Within the leukocyte populations that respond to these adjuvants, monocytes serve 
as the primary antigen-internalizing cells at the site of injection, and appear to transport the 
antigen to draining lymph nodes for B cells and DC presentation of the antigen to T cells.25,29 
Lately, adjuvants currently under development are generally comprised of ligands of novel targets 
such as the TLRs. AS04 contains the only TLR ligand currently approved by the FDA. However, 
there are several pure TLR agonists in clinical trials and many more in preclinical development, 
including some of the compounds described in this work. Some of the TLR agonists in current 
clinical trials include TLR9 active CpG DNA (phase III), TLR5/NLRC4 ligand flagellin (phase II), 
and TLR4 active glucopyranosyl lipid A (phase I).30 Given that TLRs appear to be key to bridging 
the innate and adaptive immune systems, targeting these receptors to produce novel vaccine 
adjuvants have been a hot area of research the last decade. Depending on the TLR engaged, 
downstream responses include APC activation and maturation, leukocyte recruitment, as well as 
lymphocyte activation.  
Chapter 1.3 Toll-Like Receptors 
TLRs are ~90 kDa transmembrane protein receptors that detect various pathogens and their 
activation catalyzes innate and adaptive immune responses pathways. TLRs are predominantly 
expressed in tissues involved in immune function, such as the spleen and the peripheral blood 
leukocytes, as well as those exposed to the external environment such as the lung and the 
gastrointestinal tract.31 Their expression profiles vary among tissues and cell types. TLRs are 
located on the plasma membrane except for TLR3, TLR7, TLR8, and TLR9 which are localized 
in the endosomal compartment.32 Structurally, TLRs contain a Toll-interleukin receptor (TIR) 
domain for signal transduction, a single alpha helix spanning the membrane, and an extracellular 
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leucine-rich repeat (LRR) domain for ligand binding. TLRs can be divided into 5 subfamilies based 
on sequence similarity: TLR2, TLR3, TLR4, TLR5, and TLR9.32 Antigen presenting cells (APC) 
such as monocytes, macrophages, and DC show broad, but not identical, TLR expression 
patterns.33 Specifically, TLR7 is found in monocytes, macrophages, dendritic cells, and B cells, 
while TLR8’s distribution is similar to TLR7 but with the addition of mast cells.34 This thesis will 
focus on the TLR9 subfamily, specially TLR7 and TLR8. 
Chapter 1.4 TLR9 Subfamily 
The TLR9 subfamily consists of the endosomal receptors TLR7, -8, and -9. Within this family, 
TLR7 and TLR8 are the most closely related with 42% identity and 73% similarity in their amino 
acid sequences.35,36 Upon ligand binding, the adapter protein myeloid differentiation primary 
response gene 88 (MyD88) is recruited to the TIR domains of the TLRs, and ultimately results in 
a signal transduction to the transcription factor nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-kB), which leads to innate immune activation. The TLR9 subfamily has 
additional signal transduction to the interferon regulatory factors (IRFs), which exert transcription 
control of Type I and Type II IFNs.37  
All three members of this family naturally recognize various forms of genetic material; TLR7 and 
TLR8 both recognize single stranded RNA, while TLR9 senses unmethylated deoxycytidyl-
deoxyguanosine (CpG) motifs in DNA.32 In addition to single stranded RNA, small agonists of 
TLR7 and -8 have been identified by many research groups while small agonists of TLR9 have 
remained elusive, with only discovery of small antagonists at TLR9.38,39  While TLR7 and -8 share 
similarities in ligand recognition and both potentiate a skewed Th1 response, they do differ in 
specific cytokine responses. TLR7 stimulation results in activation of the transcription factors IRF3 
and IRF7, resulting in the secretion of the Type I interferons IFN-β and IFN-α, respectively.40 TLR8 
activates IRF1, resulting in a Type II interferon response secreting IFN-γ.41 The premise of the 




















Chapter 2.1 Introduction 
The first class of synthetic small-molecule TLR7/8 agonists were substituted guanosine 
nucleosides, such as Loxoribine. These guanosine derivatives have shown to be effective at 
activating B cells and the enhancing the production of antibodies. They have also demonstrated 
that they enhance CTLs and NK cells. Despite this promising preclinical data, guanosine 
derivatives have not been developed as vaccine adjuvants.42   
3M Pharmaceuticals in the 1980s were attempting to identify small molecules that would inhibit 
infection by herpes simplex virus (HSV)-2, a known causative agent of genital herpes. They 
identified a new structural class of molecules that demonstrated excellent antiviral activity, called 
imidazoquinolines, the most notable being Imiquimod and Resiquimod, Figure 1.43,44 Further 
studies have demonstrated that imidazoquinolines were not directly active against HSV but 
instead induced IFN-α in vivo.44 Imidazoquinolines have since also been shown to induce INF-ˠ, 
TNF- α, and several interleukins and well known TLR7/8 agonists.45–48  Today, Imiquimod is a 
known TLR7 agonist and is the active ingredient in an FDA approved topical application, Aldara®, 
used to treat skin conditions such as superficial basal cell carcinoma and actinic keratosis.49 
 
Since the discovery of imidazoquinolines by 3M Pharmaceuticals, many other groups including 
3M have developed more agonists that target TLR7. Gerster et. al. of 3M Pharmaceuticals 
performed a structural activity relationship (SAR) of IFN producing imidazoquinolines. In Gerster’ 
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s investigation, they found that simple alkyl or hydroxyalkyl substituents at N1 with unsubstituted 
C2 induced IFN. If the chain at N1 gets too bulky, activity is diminished or completely inactivated. 
Straight-chain alkyl substitution at the C2 position enhances IFN induction increasing up to butyl 
and maxing out. They also found that the amine at the C4 position appears to be the most crucial 
requirement for activity as all modifications at this position eliminated IFN production. Simple 
substitutions on the benzene ring diminished activity or eliminated it. When C2 was 
unsubstituted.50  
Since 3M Pharmaceuticals’ SAR study, others have progressed the knowledge of TLR7 agonists. 
Sunil David’s group has developed agonists specific to TLR7 or -8 as well as mixed TLR7/8 
agonists.51–53  David Ferguson’s group has recently developed new TLR7/8 agonists as well. Their 
work has shown that the C7 methyl ester regains activity when using substitutions at the N1 and 
C2 positions that Gerster discovered, with potency near to Resiquimod when using a N1 2-
hydroxy-2-methylpropyl and a C2 n-butyl group.54,55  When Gerster et. al. examined the IFN 
activity of a collection of C6−C9 substituted imidazoquinolines they did not examine the effect of 
combining N1 or C2 substitutions with C6−C9 aryl modified analogues.50 Since the discovery of 
using the N1 and C2 combinations to restore C7 methyl ester activity, nobody has checked other 
substitutions at the C7 or other positions at the benzene ring.  
In 2013 Tanji et. al. resolved the X-ray crystal structure of TLR8 with Resiquimod bound to the 
active site.  As can be seen in Figure 2, Resiquimod sits deeply in the pocket with the N1 2-
hydroxy-2-methylpropyl, and the C2 ethoxymethyl protrudes into a hydrophobic pocket.56 The 
quinoline ring forms a pi-stacking with a Phe residue. The amidine group of the quinoline moiety 
forms hydrogen bonds with the side chain of Asp543 and The N atoms of the imidazole formed 
hydrogen bonds with the amide of Thr574. The C8-postion neighbors TYR353 providing additional 





Although Imiquimod has been approved for topical use as a self-adjuvant, systemic use can be 
harmful due to systemic inflammation when concentrations get too high.57 These small molecules 
imidazoquinolines are too rapidly cleared after subcutaneous or intramuscular administration; 
thus, they cannot be targeted locally except in the case of topical administration.58 In an attempt 
to overcome this issue several groups have formulated imidazoquinolines using targeted delivery 
via covalently bonded carriers, lipophilic depots, or prodrugs.59–65 This loss of activity with 
covalently bonded conjugates is most likely due to the disruption of binding as these positions are 
Figure 2. Possible TLR7 ligand binding site based on the TLR8 structure. Green from one monomer 
of TLR8 and blue is the other monomer of TLR8. Residues with * indicate residues from the blue 
monomer. Counterpart residues of human TLR7 are shown in parentheses. Nonconserved residues 
between TLR7 and TLR8 are highlighted as red colors. Image from Tanji et al.56 
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pointed deep into the pocket as is observed from Tanji et. al. when Resiquimod is bounded to 
TLR8.56 As for the depots and prodrugs, they do show activity when released, however, the 
released drug will still cause issues systemically if concentrations get too high. Thus, there is a 
need to develop new imidazoquinoline agonists that can have linkage sites pointing away from 
the pocket and out into the endosomal aqueous lumen. In this thesis we hypothesize that the C6-
C9 positions may tolerate substitutions with C7 the most tolerant. These new substitutions could 
then be used as reactive sites to add linkers to a polymeric carrier such as hyaluronic acid.  
Chapter 2.2 Results and Discussion 
Chemistry 
Imidazoquinolines are traditionally synthesized by a modified Traube reaction to cyclize the 
imidazole ring system from a quinoline outlined in Figure 3A.50 This method allows for 
modifications of the N1 and C2 positions easily. To obtain functionalizations at the C6-C9 aryl 
positions the functional group needs to be already implemented into the precursor and must be 
able to tolerate the entire reaction sequence. This has made the development of a large synthetic 
library difficult and has left the SAR of these positions deficient in the literature.  
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The Ferguson group has developed a new strategy via highly substituted imidazoquinolines in 
approximately four steps outlined in Figure 3B.54 This strategy utilizes a Suzuki coupling reaction 
to construct a substituted biaryl precursor that is readily cyclized to the final product under mild 
conditions. This lead to the development of TLR7 imidazoquinoline agonists with a C7 methyl 
ester. They observed that a C2 butyl chain regained TLR-7/8 activity for C7 methyl ester 
imidazoquinoline.54,55 Recently, Larson et al.. recently utilized Shi’s method to investigate the SAR 
of the N1 site when the C7 methyl ester is present.66 
The synthesis of imidazoquinolines 7-19 are shown in Figure 4. The iodoimidazole precursors 
were synthesized through the multicomponent condensation of aminomalononitrile, orthoester, 
and alkyl amine. Unfortunately, this reaction sequence resulted in poor yields with several 
complications along several steps when trying to introduce new functionalities. In the paper 
describing the synthesis of the C7 methyl ester, the Ferguson group states that they used the 
amino malonitrile tosylate salt for the production of both substituted and unsubstituted C2 
imidazoquinolines in 60% yields. 54 However, in our lab the best we could get was 20%. We found 
that using diaminomaleonitrile was best for synthesizing unsubstituted C2 imidazoles while amino 
malononitrile tosylate salt was best used for synthesizing C2-substituted imidazoles. Even with 
this finding, the first step only yielded 40% of the unsubstituted C2 imidazoles. Attempting to 
synthesize bromodiaminobenzenes resulted in spontaneous decomposition due to the aryl ring 
being too electron rich and prone to air autooxidation. The diortho-substituted bromoanilines were 
too sterically hindered to either synthesize the boronic esters or the Suzuki couplings. The Suzuki 
coupling was further limited to a few substrates and it seems to only work with weakly electron 
withdrawing groups (EWGs) of the 2-bromoanilines. If the aniline was substituted a nitro group 
around the ring, the Suzuki coupling would not proceed even though EWG on aryl boronic esters 
accelerate the oxidative addition step in the catalytic cycle. A reason why this reaction fails to 




unstable in basic conditions. Also, when the NO2 is para with respect to boronic ester, the C-B 
bond has double-bond like character and is not a good leaving group for the transmetallation step 
of the Suzuki reaction. Nitrile anilines were considered but they were not commercially available 
and also would most likely not survive the ring condensation step. With these substitution 
limitations and inability to make the imidazoquinolines on large scale, we opted to use the more 
traditional route to synthesize the TLR7/8 library. Using this route, we started with a two key 
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commercially available C7 substituted quinolin-4-ols, the methoxy and the chloro (Figure 5). 
These functional groups were chosen as they would be able to withstand the reaction sequence 
as the Imiquimod version had been made previously by Gerster et al. The desired 
imidazoquinolines were synthesized in large scale and were further derivatized after the 
completion of the amination step.  
 
Synthesizing C7 substituted imidazoquinolines using the Traube strategy was found to be more 
efficient and scalable than the Ferguson group strategy. The first four reactions can be completed 
in large scale with three of the four intermediates crashing out of solution to be collected by 
vacuum filtration with the fourth being easily purified by a Celite plug and extraction. The 
cyclization is completed by refluxing in neat valeric or ethoxyacetic acid. The oxidation product is 
generated in high yields and can be purified by chromatography. The final step is amination via 
ammonia hydroxide and tosyl chloride and is purified by chromatography. The 7-methoxy 




The derivatization of 7-chloro compounds can be seen in Figure 7. The 7-chloro is converted into 
the nitrile by employing a method found by Littke et al.67 Their method worked well on all our 
imidazoquinolines with yields around 80%. From the nitrile, several derivatives could be converted 
to several analogs. The nitrile was reduced the benzylamine by reduction with lithium aluminum 
hydride. The ketone was made via the Grignard reaction with benzyl magnesium bromide. The 
carboxylic acid via hydrolysis. The carboxylic acid could also be derivatized in several ways: 





Biological Activity  
The analogues (7-21 and 27-38) were screened for TLR-7 activity in vitro using HEK-293 cells 
that were transfected with the human TLR-7 gene along with the NF-κB inducible SEAP (secreted 
embryonic alkaline phosphatase) reporter gene. This assay measures NF-κB mediated SEAP 
production spectrophotometrically following TLR-7 specific activation.  It is important to point out 
this assay is not a direct measure of receptor activation or ligand binding affinity. In addition, some 
compounds could be cytotoxic, yielding low optical densities and incomplete dose−response 
curves.  
 
A series of imidazoquinolines are reported in Table 1. Comparing Imiquimod (1) to the new 
compounds 7-14 shows that the only change tolerated was the replacement of the C7-H with a 
fluorine (10), all other changes caused a complete loss of activity. Note that 14 was not pure when 
evaluated, possible impurities are triphenylphosphine and uncyclized intermediate. Schiaffo et al. 
showed that the C2 butyl group (20) restored activity for the C7 ester (15) shown in Figure 8.55 
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In order to elucidate if a C2-butyl imidazoquinolines could restore activity of phenyl ring 
substitutions, compounds 16 to 18 and 20 to 21 were synthesized and evaluated in the hTLR7 
assay shown in Table 2. Compound 19 was attempted to be synthesized but only a small amount 
was produced and could not be separated from the mixture. Looking at this series, the activities 
of all synthesized compounds had activity. Unfortunately compounds 17 and 19 lack data to 
determine EC50 at the time of completing this thesis but did show activity. Compounds 16 was not 
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pure during evaluation. Impurity of 16 appears to be uncyclized intermediate Compounds 16, 17, 
and 19 will be resynthesized and reevaluated in the future. 
 
Table 3 shows that many compounds are in-between our two controls Imiquimod and 
Resiquimod, further suggesting that substitutions at the C7 position tolerates substitutions 
when the C2 is substituted. Comparing Resiquimod (2) to a C7-Cl (33) shows a very slight 
decrease in activity while C7-CN (37) resulted in a 16-fold decrease in activity. This 
decrease in activity of 37 could be due to the electron deficiency of the imidazoquinoline 
ring system or the C7-position favors a more lipophilic group as a 0.53 cLogP decrease 
according to ChemDraw is noted when changing -Cl to -CN. A similar trend of C7-Cl to 
C7-CN is observed when comparing compounds 30 to 34, 31 to 35, and 32 to 36 with a 
2-, 27-, and 52-fold decreases respectively. A 4-fold decrease is observed when changing 
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the C7-Cl (31) to a C7-COOH (38). The C7-COOH of 38 could be binding as the ionized 
or unionized form depending on the stage of the endosome which can range from pH 4 
to pH 6. Note that compounds 34, 35, and 38 are not pure. Impurities appear to be 
hydrolysis of the nitrile to the amide or carboxylic acid. 
Some notable compounds are the C7-meothy compounds 27 and 28, and the C7-OH, 29, 
as these are very active suggesting that the increase of electron density of the 
imidazoquinoline ring system may be increasing the H-bonding interactions of the C4-
NH2 and N5 pyridine nitrogen. Looking between N1 substitutions, a huge increase in 
activity is noted for tertiary alcohols compared those without. When C2 contains the ether 
substitution a slight decrease is observed as well. Mixtures of C2 ethers and N1 tertiary 
alcohols lie in between those without. This data suggests that area near N1 may be a H-
bonding interaction that is being exploited while C2 reaches into a very lipophilic pocket. 
The strong activity of 7-Cl, 32, is interesting and could be due to the Val near the C7 
position helping with a hydrophobic interaction or the smaller substitution could fit the 
pocket better than the than the MeO. In the future we would like to synthesize a C7-OH 
with the tertiary alcohol to see if activity increases farther. The activity of 38  and 29 is 
exciting as they can be used in future studies to help deliver imidaquinolines safely to the 
endosome by allowing access to a cleavable ester or amide linkers to drug carriers which 
can be developed further in the near future. The development of the nitrile 
imidazoquinolines can be derivatized to several other functional groups such as the 
aniline, amides, reverse amides, esters, reverse esters, benzyl alcohols, and benzyl 
amines. These functionalities will further the knowledge of the SAR of the C7 position in 
the future. 
21 
Chapter 2.3 Conclusions 
This study has found that the method developed by Shi et al. allow much access to new functional 
groups as one would hope due to several limitations. Utilizing the Traube reaction strategy proved 
more fruitful for making C7-substituted imidazoquinolines leading to the development of several 
active C7 imidazoquinoline agonists on gram scale. The most notable TLR-7 agonist developed 
from this study are 27, 28, 29, and 32 which are the most active compounds reported using the 
HEK-293 hTLR7 assay to date. This study has also yielded an active carboxylic acid analog, 38, 
which is of great interest in future studies of safely delivering TLR7 agonists as adjuvants. Now 
that the difference between N1 and C2 have been evaluated it has been concluded that both 
changes yield active compounds with different potencies, the study will narrow its focus to one 
type of substitution at the N1 and C2 positions to fully evaluate the SAR of the C7 position. Once 
the library is completed the C7-substituted imidazoquinolines will also be evaluated in HEK-293 
hTLR8 cells for activity. The best compounds will be evaluated in human PBMCs and other 
immune response assays to determine specific immunological responses. In the distant future the 
best reactive handles will be used to explore linkers attached to imidazoquinolines and then will 
be attached to hyaluronic acid to help deliver our imidazoquinolines safely and effectively in order 
to develop a novel adjuvant that will be evaluated in vivo. 
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Chapter 2.4 Experimental 
Chemistry 
General Experimental Conditions 
All solvents were used as received from commercial vendors. All starting chemicals were 
purchased from AK Scientific, Ark Pharm, AstraTech, Combi-Blocks, eNovation Chemicals, 
Fisher, Oakwood Chemical, Sigma-Aldrich, and Strem Chemicals or were synthesized using the 
cited literature protocol. Compounds 1-isobutyl-8-nitro-1H-imidazo[4,5-c]quinolin-4-amine (7) 
and 1-isobutyl-1H-imidazo[4,5-c]quinoline-4,8-diamine (8) were prepared according to the 
literature procedure according to Gerster et al. All reactions were conducted under an atmosphere 
of N2 or Ar unless stated otherwise. Thin layer chromatography (TLC) was performed on 0.25 mm 
glass-backed silica GF plates from Analtech. Developed plates were visualized with a hand-held 
UV lamp. Flash chromatography was performed on a Combiflash system using pre-packed 
columns from Teledyne-Isco. 1H and 13C NMR spectra were recorded on a 500 MHz Bruker AVIII 
spectrometer equipped with cryogenically cooled carbon observe probe or a Bruker 400 MHz 
spectrometer in the noted solvent. Peaks are reported as chemical shift (δ) are reported in ppm, 
coupling constants reported in (J) are reported in Hz, and number of protons (H) are noted from 
integrations in MestReNova software. High resolution mass spectra (HRMS) were obtained on an 
LCT Premier (Micromass Ltd., Manchester UK) time-of-flight (TOF) mass spectrometer (MS) 
equipped with an ESI interface. 
 
5-amino-1-isobutyl-1H-imidazole-4-carbonitrile (3a) 
3a was made using a modified procedure from Sun and Hosman.68 A mixture of 
diaminomaleonitrile (6 g,  55.5 mmol) and triethyl orthoformate (9.2 mL, 55.5 mmol) in anhydrous 
dioxane (95 mL) was heated at reflux in a flask fitted with a short path jacketed distilling head with 
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a 100 mL receiver. Ethanol mixed with dioxane was collected continuously until ~60 mL had been 
collected in the receiver flask. The brown residue in the distillation flask was allowed to cool to 
room temperature. When hexanes (50 mL) was added, a dark brown crystalline solid formed and 
was filtered by vacuum filtration. The mother liquor was mixed with more hexanes and cooled to 
-20 °C to collect additional solid. The combined solid was dissolved in a minimum amount of hot 
diethyl ether and filtered to remove the dark brown solid impurity. The solvent was evaporated to 
obtain a white solid intermediate to be used in the next step without further purification. The 
intermediate (3.85 g, 23.5 mmol) and anilinium chloride (50 mg, 0.39 mmol) was dissolved in 
anhydrous ethanol (75 mL) and cooled to 0°C. Isobutyl amine (2.45 mL, 24.7 mmol) was added 
dropwise at 0°C and the reaction was stirred at room temperature for 5 h. The reaction mixture 
was added dropwise to a solution of sodium hydroxide (50 mL, 0.8 M) at 0 °C for five minutes. 
The reaction mixture was stirred overnight, filtered, washed with water (2 X 20 mL), and dried to 




3b was prepared from known procedure by Shi et al.54 dried to obtain a light tan solid.  (7 g, 55% 
yield). Spectral data matched previously reported data.54 
 
General Procedure A for iodoimidazoles:  
The procedure was adapted from Shi et al.54  A solution of isoamyl nitrite (4 eq.) in CHCl3 (8 mL 
per mmol) was added to a solution of imidazole-4-carbonitrile (1 eq.) in CH2I2 (1.6 mL per mmol) 
at 80 °C over 20 min. The mixture was heated for an additional 30 min and allowed to cool to 25 
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The title compound was prepared according to the general procedure A using 3a. 4a was purified 
by Combiflash (70% EtOAc in hexanes) and was isolated as a light orange solid in 37% yield. 
Spectral data matched previously reported data.54 
 
5-iodo-2-butyl-1-(2-hydroxy-2-methylpropyl)-1H-imidazole-4-carbonitrile (4b) 
The title compound was prepared according to the general procedure A using 3b. 4b was purified 
by Combiflash (70% EtOAc in hexanes) and was isolated as a dark brown solid in 29% yield. 
Spectral data matched previously reported data.54 
 
General Procedure B for the Synthesis of Arylboronates:  
The procedure adapted from Fang et al. with modifications.69 A mixture of PdCl2(dppf) (0.03 eq), 
potassium acetate (3 eq), bis(neopentyl glycolato)diboron (1.2 eq), and arylbromide (1 eq) was 
added to a flask in a glove box filled with Argon under anhydrous conditions. After addition of 
anhydrous DMSO (8 mL per mmol of arylbromide), the mixture was stirred at 90 ºC for 5 h. The 
reaction solution was cooled to room temperature and poured into ice-water. The mixture was 
extracted with ethyl acetate and the combined organic layers were washed with saturated brine, 
dried over MgSO4, and concentrated in vacuo. The residue was purified by Combiflash to give 
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The title compound was prepared according to the general procedure B above using 2-bromo-6-
fluoroaniline. 5-1F was purified by Combiflash (10-40% EtOAc in hexanes) and was isolated as 
an off-white solid in 59% yield. 1H NMR (CDCl3, 400 MHz) δ 7.45 – 7.40 (m, 1H), 7.03 (ddd, J = 
11.7, 7.9, 1.5 Hz, 1H), 6.61 (td, J = 7.7, 4.7 Hz, 1H), 4.90 (s, 2H), 3.82 (s, 4H), 1.06 (s, 6H). HRMS 
(m/z): [M+H] calcd for C11H16BFNO2, 224.1156; found 224.1252. 
 
2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-5-fluoroaniline (5-2F) 
The title compound was prepared according to the general procedure B using 2-bromo-5-
fluoroaniline. 5-2F was purified by Combiflash (10-40% EtOAc in hexanes) and was isolated as a 
tan solid in 93% yield. 1H NMR (CDCl3, 400 MHz) δ 7.63 (dd, J = 8.4, 7.5 Hz, 1H), 6.38 (td, J = 
8.6, 2.4 Hz, 1H), 6.27 (dd, J = 11.5, 2.3 Hz, 1H), 4.95 (s, 2H), 3.80 (s, 4H), 1.05 (s, 6H). HRMS 




The title compound was prepared according to the general procedure B using 2-bromo-4-
fluoroaniline. 5-3F was purified by Combiflash (10-40% EtOAc in hexanes) and was isolated as a 
black solid in 27% yield. 1H NMR (CDCl3, 400 MHz) δ 7.31 (dd, J = 9.6, 3.2 Hz, 1H), 6.92 – 6.84 
(m, 1H), 6.52 (dd, J = 8.8, 4.3 Hz, 1H), 4.64 (s, 2H), 3.77 (s, 4H), 1.03 (s, 6H). HRMS (m/z): [M+H] 
calcd for C11H16BFNO2, 224.1156; found 224.1266. 
 
2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-3-fluoroaniline (5-4F) 
The title compound was prepared according to the general procedure B using 2-bromo-3-
fluoroaniline. 5-4F was purified by Combiflash (10-40% EtOAc in hexanes) and was isolated as a 
black oil in 10% yield. 1H NMR (CDCl3, 400 MHz) δ 7.07 (td, J = 8.1, 6.5 Hz, 1H), 6.38 – 6.31 (m, 
2H), 4.86 (s, 2H), 3.81 (s, 4H), 1.05 (s, 6H). HRMS (m/z): [M+H] calcd for C11H16BFNO2, 224.1156; 
found 224.1277. 
 
Methyl 2-amino-3-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)benzoate (5-1E) 
The title compound was prepared according to the general procedure B using methyl 3-amino-4-
bromobenzoate. 5-1E was purified by Combiflash (10-40% EtOAc in hexanes) and was isolated 
as an off-white fluffy crystalline solid in 57% yield. 1H NMR (CDCl3, 400 MHz) δ 7.69 (d, J = 7.7 
Hz, 1H), 7.28 (dd, J = 7.8, 1.5 Hz, 1H), 7.24 – 7.22 (m, 1H), 4.96 (s, 2H), 3.88 (s, 3H), 3.79 (s, 




Methyl 3-amino-4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)benzoate (5-2E) 
The title compound was prepared according to the general procedure B using methyl 2-amino-3-
bromobenzoate. 5-2E was purified by Combiflash (10-40% EtOAc in hexanes) and was isolated 
as a brown solid in 11% yield. 1H NMR (CDCl3, 400 MHz) δ 7.69 (d, J = 7.8 Hz, 1H), 7.28 (dd, J 
= 7.8, 1.6 Hz, 1H), 7.23 (dd, J = 1.5, 0.5 Hz, 1H), 4.89 (s, 2H), 3.88 (s, 3H), 3.79 (s, 4H), 1.03 (s, 
6H). HRMS (m/z): [M+H] calcd for C13H19BNO4, 264.1407; found 264.1399. 
 
Methyl 4-amino-3-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)benzoate (5-3E) 
The title compound was prepared according to the general procedure B using methyl 4-amino-3-
bromobenzoate. 5-3E was purified by Combiflash (10-40% EtOAc in hexanes) and was isolated 
as a light tan solid in 35% yield. 1H NMR (CDCl3, 400 MHz) δ 8.35 (d, J = 2.2 Hz, 1H), 7.87 – 7.78 
(m, 1H), 6.53 (d, J = 8.5 Hz, 1H), 5.25 (s, 2H), 3.84 (s, 3H), 3.79 (s, 4H), 1.03 (s, 6H). HRMS 
(m/z): [M+H] calcd for C13H19BNO4, 264.1407; found 264.1401. 
 
General Procedure C for the Synthesis Imidazoquinolines:  
The procedure was adapted from Shi et al. with modifications.54 Inside of a glovebox filled with 
Argon Pd(PPh3)4 (5%), functionalized imidazole (1.0 eq), arylboronic esters (1.5 eq), and 2 M 
Na2CO3 aqueous solution (3.0 eq) were added to an oven dried scintillation vial. 1,4-dioxane was 
added to the scintillation vial and sealed with a PTFE coated cap. The vial was taken out of the 
glovebox and the mixture was heated to 80 °C overnight. The mixture was then allowed to cool 
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to room temperature and diluted with EtOAc and H2O. The aqueous layer was extracted with 
EtOAc (3x). The combined organic layer was washed with brine, dried over MgSO4, and 
concentrated in vacuo. The resulting brown oil was loaded onto a short pad of silica gel, followed 
by flashing with CH2Cl2 (30 mL). The filtrate was concentrated in vacuo to provide the crude 
product which was used without further purification in the next step. To a round-bottom flask 
containing the crude product (1.0 eq), 4 N HCl in 1,4-dioxane (16 eq) was added. The mixture 
was heated at reflux for 4 h and then cooled to room temperature. The mixture was concentrated 
in vacuo and partitioned between 5% MeOH in DCM and saturated NaHCO3 solution. The 
aqueous layer was extracted with 5% MeOH in DCM (3x). The combined organic layers were 
washed with brine, dried over MgSO4, and concentrated in vacuo. The crude residue was purified 
by flash column chromatography on silica gel. 
 
6-fluoro-1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine (9) 
The title compound was prepared according to the general procedure C using 4a and 5-1F. 9 was 
purified by Combiflash (0-10% MeOH in DCM) and was isolated as a bright red solid in 45% yield 
over two steps.  1H NMR (500 MHz, DMSO-d6) δ 8.24 (s, 1H), 7.82 (d, J = 8.1 Hz, 1H), 7.31 – 
7.21 (m, 2H), 6.89 (s, 2H), 4.40 (d, J = 7.5 Hz, 2H), 2.51 (p, J = 1.8 Hz, 4H), 0.92 (d, J = 6.6 Hz, 
6H); 13C NMR (126 MHz, DMSO-d6) δ 156.78 (d, J = 247.6 Hz), 152.73, 144.30, 134.69 (d, J = 
11.4 Hz), 131.97 (d, J = 4.2 Hz), 129.03, 121.14 (d, J = 8.4 Hz), 117.43 (d, J = 3.6 Hz), 116.88 
(d, J = 4.1 Hz), 112.27 (d, J = 19.5 Hz), 53.87, 28.89, 19.76. HRMS (m/z): [M+Na] calcd for 






The title compound was prepared according to the general procedure C using 4a and 5-2F. 10 
was purified by Combiflash (0-10% MeOH in DCM) and was isolated as a light red solid in 36% 
yield over two steps. 1H NMR (500 MHz, DMSO-d6) δ 8.17 (s, 1H), 8.03 (dd, J = 9.0, 6.3 Hz, 1H), 
7.30 (dd, J = 11.4, 2.7 Hz, 1H), 7.14 (td, J = 8.8, 2.8 Hz, 1H), 6.80 (s, 2H), 4.38 (d, J = 7.5 Hz, 
2H), 2.14 (h, J = 13.8, 6.9 Hz, 1H), 0.91 (d, J = 6.6 Hz, 6H); 13C NMR (126 MHz, DMSO-d6) δ 
161.05 (d, J = 241.9 Hz), 153.03, 146.54 (d, J = 12.3 Hz), 143.30, 131.76, 127.54, 122.50 (d, J = 
10.1 Hz), 111.94 – 111.79 (m), 110.21 (d, J = 20.4 Hz), 109.63 (d, J = 23.7 Hz), 53.27, 28.34, 
19.31.HRMS (m/z): [M+H] calcd for C14H16FN4, 259.1359; found 259.1334. 
 
8-fluoro-1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine (11)  
The title compound was prepared according to the general procedure C using 4a and 5-3F. 11 
was purified by Combiflash (0-10% MeOH in DCM) and was isolated as a light orange solid in 
42% yield over two steps. 1H NMR (500 MHz, DMSO-d6) δ 8.22 (s, 1H), 7.71 (dd, J = 10.4, 2.9 
Hz, 1H), 7.64 (dd, J = 9.2, 5.7 Hz, 1H), 7.33 (td, J = 8.8, 2.8 Hz, 1H), 6.63 (s, 2H), 4.40 (d, J = 7.5 
Hz, 2H), 2.13 (hept, J = 6.8 Hz, 1H), 0.91 (d, J = 6.6 Hz, 6H); 13C NMR (126 MHz, DMSO-d6) δ 
156.81 (d, J = 237.1 Hz), 151.69, 143.83, 141.65, 131.81 – 130.79 (m), 128.75 (d, J = 12.9 Hz), 
127.96 (d, J = 8.9 Hz), 115.22 (d, J = 23.9 Hz), 114.65 (d, J = 9.5 Hz), 105.26 (d, J = 24.1 Hz), 




The title compound was prepared according to the general procedure C using 4a and 5-4F. 12 
was purified by Combiflash (0-10% MeOH in DCM) and was isolated as an orange solid in 23% 
yield over two steps. 1H NMR (500 MHz, DMSO-d6) δ 8.10 (s, 1H), 7.58 (dddd, J = 36.0, 8.3, 6.6, 
2.4 Hz, 3H), 3.83 (d, J = 7.5 Hz, 2H), 2.06 (dp, J = 13.9, 6.9 Hz, 1H), 0.85 (d, J = 6.7 Hz, 6H); 13C 
NMR (126 MHz, DMSO-d6) δ 142.85, 132.71 (d, J = 102.4 Hz), 132.68 (d, J = 11.3 Hz), 132.01 
(d, J = 2.7 Hz), 131.47 (d, J = 9.9 Hz), 129.75 (d, J = 6.2 Hz), 128.73 (d, J = 11.8 Hz), 120.19, 
115.59, 88.23, 54.79, 28.91, 19.26. HRMS (m/z): [M+H] calcd for C14H16FN4, 259.1359; found 
259.1351. 
 
Methyl 4-amino-1-isobutyl-1H-imidazo[4,5-c]quinoline-7-carboxylate (13) 
The title compound was prepared according to the general procedure C using 4a and 5-2E. 14 
was purified by Combiflash (0-10% MeOH in DCM) and was isolated as a red solid in 59% yield 
over two steps.  1H NMR (500 MHz, DMSO-d6) δ 8.28 (d, J = 1.5 Hz, 1H), 8.19 (t, J = 1.4 Hz, 1H), 
8.10 (dd, J = 8.6, 1.8 Hz, 1H), 7.78 (dt, J = 8.5, 1.9 Hz, 1H), 6.85 (s, 2H), 4.42 (dd, J = 7.5, 1.7 
Hz, 2H), 3.89 (d, J = 1.4 Hz, 3H), 2.24 – 2.09 (m, 1H), 0.91 (dd, J = 6.6, 1.7 Hz, 6H); 13C NMR 
(126 MHz, DMSO-d6) δ 166.50, 152.91, 144.39, 144.37, 131.20, 129.44, 127.53, 127.49, 120.95, 
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120.69, 118.12, 53.44, 52.16, 28.50, 19.30. HRMS (m/z): [M+H] calcd for C16H19N4O2, 299.1508; 
found 299.1535. 
 
Methyl 4-amino-1-isobutyl-1H-imidazo[4,5-c]quinoline-8-carboxylate (14) 
The title compound was prepared according to the general procedure C using 4a and 5-3E. 15 
was purified by Combiflash (0-10% MeOH in DCM) and was isolated as a light tan solid in 31% 
yield over two steps.  1H NMR (500 MHz, DMSO-d6) δ 8.63 (d, J = 2.0 Hz, 1H), 8.28 (s, 1H), 7.96 
(dd, J = 8.7, 1.9 Hz, 1H), 7.65 (d, J = 8.7 Hz, 1H), 7.10 (s, 2H), 4.42 (d, J = 7.2 Hz, 2H), 3.90 (s, 
3H), 2.24 – 2.08 (m, 1H), 1.00 (d, J = 6.7 Hz, 6H); HRMS (m/z): [M+H] calcd for C16H19N4O2, 
299.1508; found 299.1527. 
 
6-fluoro-1-(2-hydroxy-2-methylpropyl)-2-butyl-1H-imidazo[4,5-c]quinoline-4-amine (16) 
The title compound was prepared according to the general procedure C using 4b and 5-1F. 16 
was purified by Combiflash (0-10% MeOH in DCM) and was isolated as a light tan solid in 41% 
yield over two steps.  1H NMR (500 MHz, DMSO-d6) δ 8.63 (d, J = 2.0 Hz, 1H), 8.28 (s, 1H), 7.65 
(d, J = 8.7 Hz, 1H), 7.10 (s, 2H), 4.42 (d, J = 7.2 Hz, 2H), 3.90 (s, 3H), 2.22 – 2.10 (m, 1H), 1.00 




The title compound was prepared according to the general procedure C using 4b and 5-2F. 17 
was purified by Combiflash (0-10% MeOH in DCM) and was isolated as a light tan solid in 36% 
yield over two steps. 1H NMR (400 MHz, Chloroform-d) δ 8.15 (dd, J = 9.2, 5.9 Hz, 1H), 7.40 (dd, 
J = 10.7, 2.7 Hz, 1H), 7.04 (ddd, J = 9.2, 8.0, 2.7 Hz, 1H), 5.73 (s, 2H), 4.54 (s, 2H), 3.01 – 2.76 
(m, 2H), 1.89 – 1.74 (m, 2H), 1.45 (dp, J = 14.6, 7.4 Hz, 2H), 1.36 (s, 6H), 0.98 (t, J = 7.4 Hz, 3H). 




The title compound was prepared according to the general procedure C using 4b and 5-3F. 18 
was purified by Combiflash (0-10% MeOH in DCM) and was isolated as a brown solid in 50% 
yield over two steps.  1H NMR (500 MHz, DMSO-d6) δ 8.07 (d, J = 8.3 Hz, 1H), 7.24 – 7.16 (m, 
1H), 7.13 (td, J = 8.1, 5.3 Hz, 1H), 6.67 (s, 2H), 4.78 (s, 1H), 4.53 (s, 2H), 3.03 (t, J = 7.8 Hz, 2H), 
1.84 – 1.74 (m, 2H), 1.42 (h, J = 7.4 Hz, 2H), 1.16 (s, 6H), 0.94 (t, J = 7.4 Hz, 3H); 13C NMR (126 
MHz, DMSO-d6) δ 156.27 (d, J = 246.4 Hz), 155.60, 151.76, 134.13 (d, J = 10.2 Hz), 133.29 (d, 
J = 4.1 Hz), 126.63, 119.60 (d, J = 8.2 Hz), 117.59 (d, J = 3.3 Hz), 117.20 (d, J = 4.0 Hz), 110.90 
(d, J = 19.5 Hz), 70.74, 54.54, 29.77, 26.97, 26.85, 22.05, 13.86. HRMS (m/z): [M+H] calcd for 





The title compound was prepared according to the general procedure C using 4b and 5-2E. 20 
was purified by Combiflash (0-10% MeOH in DCM) and was isolated as a light tan solid in 43% 




The title compound was prepared according to the general procedure C using 4b and 5-3E. 21 
was purified by Combiflash (0-10% MeOH in DCM) and was isolated as a brown solid in 37% 












The procedure was adapted from Gerster et al. with modifications.50  In a round bottom flask, 7-
methoxy-quinolin-4-ol was suspended in propionic acid and heated to reflux with a  water cooled 
condenser opened to air. 70% nitric acid (1.8 eq.) was added dropwise over 15 minutes. The 
reaction was refluxed for 2 hours. The reaction was allowed to cool to room temperature and the 
solid was collected by vacuum filtration. The solid was washed with cold EtOH, followed by 




The procedure was adapted from Gerster et al. with modifications.50 In a round bottom flask, 7-
chloro-quinolin-4-ol was suspended in propionic acid and heated to reflux with a  water cooled 
condenser opened to air. 70% nitric acid (2.2 eq.) was added dropwise over 15 minutes. The 
reaction was refluxed for 1 h. The reaction was allowed to cool to room temperature and diluted 
with EtOH and the solid was collected by vacuum filtration. The solid was washed with cold EtOH, 
followed by hexanes and 22b was isolated in 70% yield as a tan solid. Spectral data matched 
previously reported data.50 
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General Procedure D (Step 2): 
The procedure was adapted from Gerster et al. with modifications.50 Phosphorus oxychloride (1.2 
eq.) was added dropwise to a well stirred suspension of  7-substituted-nitroquinoline-4-ol in 
anhydrous DMF (1.8 mL per mmol) and an exothermic reaction was observed. After addition of 
POCl3 was completed, the reaction was heated at 50 °C and stirred for 30 min. The resulting 
solution was cooled to room temperature and poured into ice water (7.5 mL per mmol). The 
resulting solid was collected by vacuum filtration, washed with water and pressed dry. The moist 
solid was added to a round bottom flask and suspended in EtOH (5 mL per mmol), Et3N (2 eq.), 
and the appropriate alkyl amine (1.3 eq.) and refluxed for 15 min. Water was added to the solution 
and the solid was collected by vacuum filtration.  
 
7-methoxy-N-isobutyl-3-nitroquinolin-4-amine (23a)  
The title compound was prepared according to the general procedure D using 22a and 
isobutylamine to obtain a bright yellow solid in 80% yield. Spectral data matched previously 
reported data.50 
 
1-((7-methoxy-3-nitroquinolin-4-yl)amino)-2-methylpropan-2-ol (23b)  
The title compound was prepared according to the general procedure D using 22a and 1-Amino-
2-methyl-2-propanol to obtain a bright yellow solid in 80% yield. 1H NMR (400 MHz, Methanol-d4) 
δ 9.20 (s, 1H), 8.38 (d, J = 9.5 Hz, 1H), 7.28 (d, J = 2.7 Hz, 1H), 7.19 (dd, J = 9.4, 2.7 Hz, 1H), 
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4.59 (s, 2H), 3.97 (s, 3H), 3.91 (s, 2H), 1.29 (s, 6H); HRMS (m/z): [M+H] calcd for C14H18N3O4, 
292.1297; found 292.1309. 
 
7-chloro-N-isobutyl-3-nitroquinolin-4-amine (23c) 
The title compound was prepared according to the general procedure D using 22b and 
isobutylamine to obtain a bright yellow solid in 80% yield. Spectral data matched previously 
reported data.50 
 
1-((7-chloro-3-nitroquinolin-4-yl)amino)-2-methylpropan-2-ol (23d)  
The title compound was prepared according to the general procedure D using 22b and 1-Amino-
2-methyl-2-propanol to obtain a bright yellow solid in 80% yield. 1H NMR (CDCl3, 500 MHz) δ 9.93 
(s, 1H), 9.37 (s, 1H), 8.18 (d, J = 9.0 Hz, 1H), 7.99 (d, J = 2.4 Hz, 1H), 7.44 (dd, J = 9.1, 2.3 Hz, 
1H), 3.85 (d, J = 4.9 Hz, 2H), 1.36 (s, 6H). HRMS (m/z): [M+H] calcd for C13H15ClN3O3, 296.0802; 
found 296.0813. 
General Procedure E (Step 3): 
A suspension of 7-substituted amino nitroquinoline in EtOH was heated to reflux in open air. Iron 
(dust 5 eq.) was added followed by aqueous NH4Cl (2.3 M, 5eq.) and refluxed for 2 hours. The 
solution was allowed to cool and was filtered through a Celite plug and eluted with EtOAc. The 
volume of solvent was reduced on a rotovap and basified with saturated Na2CO3. The aqueous 
37 
layer was extracted with EtOAc (3x). The combined organic layers were dried with Na2SO4, 
filtered, and evaporated on rotovap to dryness.  
 
7-methoxy-N4-isobutylquinoline-3,4-diamine (24a)  
The title compound was prepared according to the general procedure E using 23a to obtain an 
orange solid in 80% yield. Spectral data matched previously reported data.50 
 
1-((3-amino-7-methoxyquinolin-4-yl)amino)-2-methylpropan-2-ol (24b)  
The title compound was prepared according to the general procedure E using 23b to obtain an 
orange solid in 80% yield. 1H NMR (400 MHz, Methanol-d4) δ 8.34 (d, J = 9.6 Hz, 1H), 8.01 (s, 
1H), 7.20 (dd, J = 9.5, 2.6 Hz, 1H), 7.11 (d, J = 2.6 Hz, 1H), 3.97 (s, 3H), 3.94 (s, 2H), 1.31 (s, 
6H). HRMS (m/z): [M+H] calcd for C14H19N3O2, 262.1555; found 262.168.f 
 
7-chloro-N4-isobutylquinoline-3,4-diamine (24c) 
The title compound was prepared according to the general procedure E using 23c to obtain an 
orange solid in 80% yield. Spectral data matched previously reported data.50 
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1-((3-amino-7-chloroquinolin-4-yl)amino)-2-methylpropan-2-ol (24d)  
The title compound was prepared according to the general procedure E using 23d to obtain an 
orange solid in 80% yield. 1H NMR (CDCl3, 400 MHz) δ 8.84 (s, 1H), 8.16 (dd, J = 9.0, 0.5 Hz, 
1H), 8.13 – 8.09 (d, 1H), 7.63 (dd, J = 9.0, 2.1 Hz, 1H), 4.60 (s, 2H), 3.90 (s, 2H), 1.28 (s, 6H); 
HRMS (m/z): [M+H] calcd for C13H14ClN3O3, 296.0802; found 296.0812. 
 
General Procedure F (Step 4): 
Valeric or ethoxy acetic acid (10 eq.) was added to diaminoquinolines in a small round bottom 
flask. The suspension was heated to reflux (~150 °C) in open air until water ceased to be released 
from the reaction. The reaction was allowed to cool and diluted with water then basified with 6M 
NaOH. The water was extracted with DCM (3x) and the combined organic layer was washed with 
brine and dried with Na2SO4, filtered, and concentrated on rotovap. The compound was purified 
by Combiflash (0-10% MeOH in DCM). 
 
2-butyl-7-methoxy-1-isobutyl-1H-imidazo[4,5-c]quinoline (25a)  
The title compound was prepared according to the general procedure F using 24a to obtain a 
brown solid in 80% yield. 1H NMR (400 MHz, Chloroform-d) δ 9.21 (s, 1H), 7.98 (d, J = 9.2 Hz, 
1H), 7.65 (d, J = 2.7 Hz, 1H), 7.29 – 7.26 (m, 1H), 4.27 (d, J = 7.6 Hz, 2H), 3.96 (s, 4H), 3.03 – 
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2.88 (m, 2H), 2.40 – 2.27 (m, 1H), 1.94 (dq, J = 9.2, 7.6 Hz, 2H), 1.50 (dt, J = 14.1, 7.2 Hz, 4H), 
1.01 (m, J = 7.0, 5.6 Hz, 9H). HRMS (m/z): [M+H] calcd for C19H26N3O, 312.2076; found 312.2086. 
 
1-(2-butyl-7-methoxy-1H-imidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol (25b)  
The title compound was prepared according to the general procedure F using 24b to obtain a 
brown solid in 80% yield. 1H NMR (400 MHz, Chloroform-d) δ 8.94 (s, 1H), 8.53 (s, 1H), 7.81 (s, 
1H), 7.33 (d, J = 9.4 Hz, 1H), 4.62 (s, 2H), 3.97 (s, 1H), 3.88 (s, 3H), 3.06 (t, 2H), 1.95 (p, J = 7.8 
Hz, 2H), 1.52 (q, J = 7.5 Hz, 2H), 1.47 (s, 6H), 1.01 (t, J = 7.3 Hz, 2H). HRMS (m/z): [M+H] calcd 
for C19H26N3O2, 328.2025; found 328.2019. 
 
2-butyl-7-chloro-1-isobutyl-1H-imidazo[4,5-c]quinoline (25c) 
The title compound was prepared according to the general procedure F using 24c to obtain a 
brown solid in 80% yield. 1H NMR (CDCl3, 500 MHz) δ 9.27 (s, 1H), 8.38 (d, J = 2.2 Hz, 1H), 8.05 
(d, J = 9.0 Hz, 1H), 7.62 (dd, J = 9.0, 2.2 Hz, 1H), 4.32 (d, J = 7.5 Hz, 2H), 2.99 – 2.93 (m, 2H), 
2.33 (hept, J = 7.0 Hz, 1H), 1.96 (ddd, J = 15.5, 8.3, 6.8 Hz, 2H), 1.52 (dd, J = 15.1, 7.5 Hz, 2H), 
1.03 (d, J = 6.7 Hz, 6H), 1.02 (t, J = 7.4 Hz, 3H).; 13C NMR (CDCl3, 126 MHz) δ 157.17, 136.50, 
133.10, 127.57, 121.28, 116.03, 53.43, 52.83, 29.54, 29.18, 27.62, 22.64, 21.79, 19.84, 13.86. 




The title compound was prepared according to the general procedure F using 24c to obtain a 
brown solid in 80% yield. 1H NMR (400 MHz, Chloroform-d) δ 9.30 (s, 1H), 8.35 (s, 1H), 8.07 (d, 
J = 9.0 Hz, 1H), 7.64 (dd, J = 8.9, 2.2 Hz, 1H), 4.89 (s, 2H), 4.51 (d, J = 7.7 Hz, 2H), 3.61 (q, J = 
7.0 Hz, 2H), 2.37 (tt, J = 13.3, 6.7 Hz, 1H), 1.25 (t, J = 7.0 Hz, 3H), 1.09 – 1.00 (m, 6H). HRMS 
(m/z): [M+H] calcd for C17H21ClN3O, 318.1373; found 318.1366. 
 
1-(2-butyl-7-chloro-1H-imidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol (25e) 
The title compound was prepared according to the general procedure F using 24d to obtain a 
brown solid in 80% yield. 1H NMR (400 MHz, Chloroform-d) δ 8.99 (s, 1H), 8.52 (d, J = 9.0 Hz, 
1H), 8.13 (s, 1H), 7.55 (dd, J = 9.1, 2.2 Hz, 1H), 4.62 (s, 2H), 3.06 (s, 2H), 1.95 (p, J = 7.7 Hz, 
2H), 1.51 (dd, J = 15.2, 7.5 Hz, 2H), 1.46 (s, 6H), 1.01 (t, J = 7.3 Hz, 3H). HRMS (m/z): [M+H] 







The title compound was prepared according to the general procedure F using 24d to obtain a 
brown solid in 80% yield. 1H NMR (400 MHz, Chloroform-d) δ 9.14 (s, 1H), 8.41 (s, 1H), 8.25 (s, 
1H), 7.60 (d, J = 8.9 Hz, 1H), 4.99 (s, 2H), 4.83 (s, 2H), 3.65 (q, J = 7.0 Hz, 2H), 1.40 (s, 6H), 1.25 
(dd, J = 7.4, 6.7 Hz, 3H). HRMS (m/z): [M+H] calcd for C17H21ClN3O2, 334.1322; found 334.1328. 
General Procedure G (Step 5): 
The procedure was adapted from Gerster et al. with modifications.50 In a round bottom flask, 
imidazoquinoline was dissolved in CHCl3 and stirred at room temperature. mCPBA (1 eq + 1eq) 
was added portion wise 1 h apart. After 3 hours the reaction was diluted with DCM, washed with 
saturated Na2CO3 aqueous solution, extracted with DCM (3x), dried with Na2SO4, filtered, and 
concentrated on rotovap. The compound was purified by Combiflash (0-10% MeOH in DCM). 
 
2-butyl-7-methoxy-1-isobutyl-1H-imidazo[4,5-c]quinoline 5-oxide (26a)  
The title compound was prepared according to the general procedure G using 25a to obtain a 
brown solid in 80% yield. 1H NMR (DMSO-d6, 500 MHz) δ 8.99 (s, 1H), 8.24 (d, J = 9.0 Hz, 1H), 
8.22 (d, J = 2.8 Hz, 1H), 7.47 (dd, J = 9.2, 2.9 Hz, 1H), 4.37 (d, J = 7.6 Hz, 2H), 2.91 (t, J = 7.6 
Hz, 2H), 2.13 (dt, J = 13.5, 6.8 Hz, 1H), 1.82 (p, J = 7.5 Hz, 2H), 1.44 (h, J = 7.4 Hz, 2H), 0.94 (t, 
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J = 7.5 Hz, 3H), 0.91 (d, J = 6.7 Hz, 6H); 13C NMR (DMSO-d6, 126 MHz) δ 158.67, 157.18, 139.13, 
134.35, 129.30, 126.50, 123.02, 120.00, 112.15, 100.90, 55.61, 51.30, 28.95, 28.60, 26.40, 21.84, 
19.15, 13.79. HRMS (m/z): [M+H] calcd for C19H26N3O2, 328.2025; found 328.2034. 
 
2-butyl-7-methoxy-1-(2-hydroxy-2-methylpropyl)-1H-imidazo[4,5-c]quinoline 5-oxide (26b)  
The title compound was prepared according to the general procedure G using 25b to obtain a 
brown solid in 80% yield. 1H NMR (400 MHz, Chloroform-d) δ 8.67 (d, J = 9.3 Hz, 1H), 8.02 (s, 
1H), 7.52 (d, J = 2.7 Hz, 1H), 7.19 (dd, J = 9.3, 2.8 Hz, 1H), 4.10 (s, 1H), 3.83 (s, 3H), 3.43 (d, J 
= 3.8 Hz, 1H), 2.92 (s, 3H), 1.86 (q, J = 7.7 Hz, 2H), 1.30 (d, J = 2.0 Hz, 2H), 0.98 (t, J = 7.4 Hz, 
3H). HRMS (m/z): [M+H] calcd for C19H26N3O3, 344.1974; found 344.1986. 
 
2-butyl-7-chloro-1-isobutyl-1H-imidazo[4,5-c]quinoline 5-oxide (26c) 
The title compound was prepared according to the general procedure G using 25c to obtain a 
brown solid in 80% yield. 1H NMR (CDCl3, 500 MHz) δ 9.58 (s, 1H), 8.88 (d, J = 2.0 Hz, 1H), 8.20 
(d, J = 9.0 Hz, 1H), 7.86 (dd, J = 9.0, 2.2 Hz, 1H), 4.39 (d, J = 7.6 Hz, 2H), 3.04 – 2.97 (m, 2H), 
2.30 (dt, J = 13.8, 6.9 Hz, 1H), 1.97 (p, J = 7.6 Hz, 2H), 1.52 (ddd, J = 14.2, 7.2, 5.4 Hz, 3H), 1.07 
(d, J = 6.7 Hz, 6H), 1.03 (t, J = 7.3 Hz, 3H); HRMS (m/z): [M+Na] calcd for C18H22ClN3ONa, 
354.1349; found 354.1362. 
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7-chloro-2-(ethoxymethyl)-1-isobutyl-1H-imidazo[4,5-c]quinoline 5-oxide (26d) 
The title compound was prepared according to the general procedure G using 25d to obtain a 
brown solid in 80% yield. 1H NMR (400 MHz, DMSO-d6) δ 9.12 (d, J = 9.9 Hz, 1H), 8.83 – 8.73 
(m, 1H), 8.40 (dd, J = 20.5, 9.0 Hz, 1H), 7.92 (ddd, J = 10.9, 8.9, 2.4 Hz, 1H), 4.80 (s, 2H), 4.55 
– 4.43 (m, 2H), 3.59 (q, J = 7.0 Hz, 2H), 2.22 (p, J = 7.1 Hz, 1H), 1.16 (t, J = 7.0 Hz, 3H), 0.92 (d, 
J = 6.7 Hz, 6H). HRMS (m/z): [M+Na] calcd for C17H20ClN3O2Na, 372.1091; found 372.1099. 
 
2-butyl-7-chloro-1-(2-hydroxy-2-methylpropyl)-1H-imidazo[4,5-c]quinoline 5-oxide (26e) 
The title compound was prepared according to the general procedure G using 25e to obtain a 
brown solid in 80% yield. 1H NMR (400 MHz, Chloroform-d) δ 9.04 (s, 1H), 8.72 (d, J = 9.1 Hz, 
1H), 8.48 (s, 1H), 7.65 (d, J = 8.5 Hz, 1H), 4.48 (s, 2H), 3.01 (s, 2H), 1.93 (p, J = 7.7 Hz, 2H), 1.51 
(dt, J = 15.0, 7.4 Hz, 2H), 1.44 (s, 6H), 1.23 (d, J = 16.9 Hz, 1H), 1.01 (t, J = 7.3 Hz, 3H). HRMS 






The title compound was prepared according to the general procedure G using 25f to obtain a 
brown solid in 80% yield. 1H NMR (CDCl3, 500 MHz) δ 9.18 (s, 1H), 8.66 (d, J = 8.9 Hz, 1H), 8.64 
– 8.60 (m, 1H), 7.73 (d, J = 8.3 Hz, 1H), 4.97 (s, 2H), 4.80 (s, 2H), 3.61 (q, J = 7.0 Hz, 2H), 1.41 
(s, 6H), 1.24 (t, J = 7.0 Hz, 3H). HRMS (m/z): [M+Na] calcd for C17H20ClN3O2Na, 372.1091; found 
372.1085. 
 
General Procedure H (Step 6): 
The procedure was adapted from Gerster et al. with modifications.50 Concentrated NH4OH (1 mL 
per mmol) was added to a round bottom flask containing N-oxide imidazoquinoline (1 eq) in 
anhydrous DCM (1 mL per mmol) stirring vigorously at room temperature. p-TsCl (1.1 eq) was 
added to an addition funnel and dissolved in anhydrous DCM (1 mL per mmol). The p-TsCl in 
DCM was added dropwise slowly over 15 min minutes and more DCM was added to help push 
residual p-TsCl into the flask to the round bottom. An exotherm was observed during the addition. 
The reaction was allowed to stir for another 15 min after addition of p-TsCl was completed. Water 
was added and if precipitate formed, the solid was isolated by vacuum filtration. The mother liquor 
or biphasic mixture was extracted with DCM, washed with brine, dried with Na2SO4, and 
concentrated in vacuo and purified by silica gel flash chromatography. 
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2-butyl-7-methoxy-1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine (27)  
The title compound was prepared according to the general procedure H using 26a to obtain a 
brown solid in 80% yield. 1H NMR (CDCl3, 500 MHz) δ 7.76 (d, J = 9.0 Hz, 1H), 7.30 (d, J = 2.7 
Hz, 1H), 7.00 (dd, J = 9.0, 2.6 Hz, 1H), 6.43 (s, 2H), 4.20 (d, J = 7.6 Hz, 2H), 3.92 (s, 3H), 2.90 – 
2.83 (m, 2H), 2.31 (dp, J = 13.4, 6.6 Hz, 1H), 1.86 (p, J = 7.6 Hz, 2H), 1.49 (h, J = 7.4 Hz, 2H), 
1.02 – 0.97 (m, 9H); 13C NMR (CDCl3, 126 MHz) δ 159.49, 154.41, 150.80, 134.77, 124.73, 
121.28, 114.23, 108.69, 105.40, 55.70, 52.71, 30.01, 29.28, 27.58, 22.73, 19.92, 19.79, 13.99. 
HRMS (m/z): [M+H] calcd for C19H27N4O, 327.2185; found 327.2196. 
 
1-(4-amino-2-butyl-7-methoxy-1H-imidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol (28)  
The title compound was prepared according to the general procedure H using 26b to obtain a 
brown solid in 80% yield. 1H NMR (500 MHz, DMSO-d6) δ 9.12 (d, J = 10.7 Hz, 1H), 8.80 (dd, J 
= 5.0, 2.3 Hz, 1H), 8.40 (dd, J = 20.5, 9.1 Hz, 1H), 7.91 (ddd, J = 11.1, 9.0, 2.4 Hz, 1H), 4.80 (s, 
1H), 4.49 (s, J = 21.9, 7.7 Hz, 2H), 3.59 (q, J = 7.0 Hz, 2H), 2.22 (p, J = 7.0 Hz, 1H), 1.16 (t, J = 
7.0 Hz, 3H), 0.92 (d, J = 6.6 Hz, 6H). 13C NMR (126 MHz, DMSO-d6) δ 157.65, 154.34, 151.79, 
146.23, 134.09, 124.72, 122.33, 110.62, 109.58, 106.88, 70.79, 54.87, 54.46, 48.59, 29.80, 26.76, 




The title compound was prepared according to the general procedure H using 26c to obtain a 
brown solid in 81% yield. 1H NMR (DMSO-d6, 500 MHz) δ 7.97 (d, J = 8.9 Hz, 1H), 7.56 (d, J = 
2.3 Hz, 1H), 7.26 (dd, J = 8.8, 2.3 Hz, 1H), 6.69 (s, 2H), 4.33 (d, J = 7.6 Hz, 2H), 2.93 – 2.87 (m, 
2H), 2.11 (dq, J = 13.8, 6.9 Hz, 1H), 1.85 – 1.76 (m, 2H), 1.44 (dt, J = 14.7, 7.4 Hz, 2H), 0.95 (t, 
J = 7.4 Hz, 3H), 0.91 (d, J = 6.6 Hz, 6H); 13C NMR (DMSO-d6, 126 MHz) δ 153.99, 152.59, 145.83, 
132.08, 130.51, 126.58, 124.81, 121.97, 120.90, 113.57, 51.31, 29.65, 28.82, 26.43, 21.93, 19.16, 
13.81. HRMS (m/z): [M+] calcd for C18H23ClN4, 330.1611; found 330.1630. 
 
7-chloro-2-(ethoxymethyl)-1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine (31) 
The title compound was prepared according to the general procedure H using 26d to obtain a 
brown solid in 78% yield. 1H NMR (500 MHz, DMSO-d6) δ 8.01 (d, J = 8.8 Hz, 1H), 7.58 (d, J = 
2.3 Hz, 1H), 7.27 (dd, J = 8.8, 2.3 Hz, 1H), 6.88 (s, 2H), 4.75 (s, 2H), 4.42 (d, J = 7.7 Hz, 2H), 
3.56 (q, J = 7.0 Hz, 2H), 2.20 (hept, J = 6.9 Hz, 1H), 1.15 (t, J = 7.0 Hz, 3H), 0.91 (d, J = 6.6 Hz, 
6H); 13C NMR (126 MHz, DMSO-d6) δ 152.93, 149.72, 146.29, 132.82, 131.12, 126.48, 124.82, 
122.43, 121.00, 113.45, 65.41, 64.16, 51.77, 28.61, 19.25, 14.92. HRMS (m/z): [M+H] calcd for 




The title compound was prepared according to the general procedure H using 26e to obtain a 
brown solid in 73% yield. 1H NMR (CDCl3, 500 MHz) δ 8.29 (d, J = 8.9 Hz, 1H), 7.53 (d, J = 2.3 
Hz, 1H), 7.17 (dd, J = 8.8, 2.3 Hz, 1H), 6.63 (s, 2H), 4.77 (s, 1H), 4.51 (s, 2H), 3.00 (t, 2H), 1.78 
(ddd, J = 15.4, 8.9, 7.1 Hz, 2H), 1.42 (h, J = 7.4 Hz, 2H), 1.16 (s, 6H), 0.94 (t, J = 7.4 Hz, 3H); 13C 
NMR (CDCl3, 126z MHz) δ 155.39, 152.57, 145.93, 133.30, 130.16, 126.28, 124.58, 123.17, 
120.10, 114.26, 70.76, 54.49, 48.59, 29.78, 26.80, 22.03, 13.86. HRMS (m/z): [M+H] calcd for 




The title compound was prepared according to the general procedure H using 26f to obtain a 
brown solid in 84% yield. 1H NMR (DMSO-d6, 500 MHz) δ 8.30 (d, J = 8.9 Hz, 1H), 7.54 (d, J = 
2.3 Hz, 1H), 7.19 (dd, J = 8.8, 2.3 Hz, 1H), 6.79 (s, 2H), 4.88 (s, 1H), 4.64 (s, 2H), 3.51 (q, J = 7.0 
Hz, 2H), 1.16 (s, 6H), 1.13 (t, J = 7.0 Hz, 3H); 13C NMR (DMSO-d6, 126 MHz) δ 153.38, 151.61, 
146.91, 134.40, 131.26, 126.67, 125.14, 123.86, 120.75, 114.52, 71.11, 65.80, 65.28, 55.25, 




Preparation of Aryl Nitriles: 
General Procedure I 
The procedure was adapted from Littke et al. with modifications.67 Aryl chloride (1 eq), Pd(TFA)2 
(5%), Zn (dust, 20%), TrixiePhos (10%), Zn(CN)2 (56%) were added to an oven-dried 40 mL vial 
and vacuum flushed with nitrogen three times. Anhydrous dimethylacetamide (DMAC) (0.19 M) 
was added via syringe to the sealed vial. The vial was shaken and placed on a heating mantel at 
95 °C and stirred overnight. The mixture was allowed to cool to room temperature and filtered 
through a plug of Celite using either 100% EtOAc or 20% MeOH in DCM to elute product. The 
solvent was then concentrated down and redissovled in EtOAc and washed with water (4-5x by 
10x the volume of DMAC), washed with brine and dried with sodium sulfate. Solvent was 
concentrated down on rotovap and purified by Combiflash (0-10% MeOH in DCM). 
 
4-amino-2-butyl-1-isobutyl-1H-imidazo[4,5-c]quinoline-7-carbonitrile (34) 
The title compound was prepared according to the general procedure I using 30 to obtain a brown 
solid in 80% yield. 1H NMR (500 MHz, DMSO-d6) δ 8.13 (d, J = 8.5 Hz, 1H), 7.98 (t, J = 1.5 Hz, 
1H), 7.56 (dt, J = 8.3, 1.5 Hz, 1H), 6.90 (s, 2H), 4.38 (d, J = 7.6 Hz, 2H), 2.94 (t, J = 6.3 Hz, 2H), 
2.18 – 2.06 (m, 1H), 1.83 (t, J = 7.7 Hz, 2H), 1.46 (q, J = 7.6 Hz, 2H), 0.98 – 0.94 (t, 3H), 0.93 (d, 
J = 6.6 Hz, 7H); 13C NMR (500 MHz, DMSO-d6) δ 155.29, 152.90, 144.07, 131.51, 130.47, 
128.12, 122.36, 121.70, 119.40, 118.00, 108.27, 51.38, 29.60, 28.90, 26.48, 21.91, 19.13, 13.80. 





The title compound was prepared according to the general procedure I using 31 to obtain a brown 
solid in 80% yield. 1H NMR (400 MHz, Chloroform-d) δ 8.22 (d, J = 1.7 Hz, 1H), 8.01 (d, J = 8.5 
Hz, 1H), 7.61 (dd, J = 8.5, 1.7 Hz, 1H), 6.42 (s, 2H), 4.86 (s, 2H), 4.48 (d, J = 7.7 Hz, 2H), 4.15 
(q, J = 7.1 Hz, 1H), 3.65 (q, J = 7.0 Hz, 2H), 2.36 (dt, J = 13.9, 7.0 Hz, 1H), 1.31 – 1.24 (m, 3H), 
1.07 (d, J = 6.7 Hz, 6H); 13C NMR (126 MHz, DMSO-d6) δ 151.85, 149.18, 143.94, 132.94, 
132.40, 129.13, 124.57, 122.81, 119.48, 119.06, 109.77, 66.15, 64.69, 52.50, 29.12, 19.74, 15.45. 





The title compound was prepared according to the general procedure I using 32 to obtain a brown 
solid in 80% yield. 1H NMR (500 MHz, DMSO-d6) δ 8.45 (d, J = 8.6 Hz, 1H), 7.94 (d, J = 1.8 Hz, 
1H), 7.46 (dd, J = 8.6, 1.8 Hz, 1H), 6.85 (s, 2H), 4.78 (s, 1H), 4.52 (s, 2H), 3.02 (t, J = 7.8 Hz, 
2H), 1.80 (ddd, J = 15.3, 8.9, 7.1 Hz, 2H), 1z.42 (h, J = 7.4 Hz, 2H), 1.17 (s, 6H), 0.94 (t, J = 7.4 
Hz, 3H); 13C NMR (126 MHz, DMSO-d6) δ 156.64, 152.92, 144.16, 132.82, 130.29, 127.82, 
123.04, 121.50, 119.52, 118.79, 107.94, 70.75, 54.55, 29.75, 26.88, 22.02, 13.86. HRMS (m/z): 





The title compound was prepared according to the general procedure I using 33 to obtain a brown 
solid in 80% yield. 1H NMR (500 MHz, DMSO-d6) δ 8.47 (d, J = 8.6 Hz, 1H), 7.96 (d, J = 1.8 Hz, 
1H), 7.48 (dd, J = 8.5, 1.8 Hz, 1H), 7.01 (s, 2H), 4.89 (s, 1H), 4.68 (s, 2H), 3.52 (q, J = 7.0 Hz, 
2H), 1.19 – 1.15 (m, 2H), 1.13 (t, J = 7.0 Hz, 3H); 13C NMR (126 MHz, DMSO-d6) δ 153.22, 
152.28, 144.67, 133.41, 130.35, 127.66, 123.24, 121.66, 119.38, 118.59, 108.61, 70.61, 65.43, 
64.75, 54.86, 27.58, 14.98. HRMS (m/z): [M+H] calcd for C18H22N5O2, 340.1774; found 340.1778. 
 
4-amino-2-butyl-1-isobutyl-1H-imidazo[4,5-c]quinolin-7-ol (29) 
28 (1 eq) was added to a melt of pyridine hydrochloride (10 eq) and heated at 210 °C for 30 
minutes. The reaction was allowed to cool for a few minutes and diluted with water and acidified 
with 6 N HCl to pH 1. The solid was collected by vacuum filtration and washed with hexanes and 
dried in air to obtain 29 in 75% yield as a light brown solid. 1H NMR (500 MHz, DMSO-d6) δ 14.00 
(s, 1H), 10.69 (s, 1H), 8.60 (s, 3H), 7.98 (d, J = 9.1 Hz, 1H), 7.19 (d, J = 2.4 Hz, 1H), 7.09 (dd, J 
= 9.0, 2.4 Hz, 1H), 5.10 (s, 4H), 4.35 (d, J = 7.6 Hz, 2H), 2.92 (t, J = 7.6 Hz, 2H), 2.09 (dq, J = 
13.8, 6.9 Hz, 1H), 1.81 (p, J = 7.6 Hz, 2H), 1.44 (h, J = 7.4 Hz, 2H), 0.97 – 0.90 (m, 9H); 13C NMR 
(126 MHz, DMSO-d6) δ 158.73, 155.98, 148.63, 135.85, 135.55, 123.38, 122.04, 115.11, 105.18, 
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102.76, 51.49, 29.25, 28.73, 26.38, 21.84, 19.11, 13.81. HRMS (m/z): [M+H] calcd for C18H25N4O 
313.2028; found 313.2041 
 
4-amino-2-(ethoxymethyl)-1-isobutyl-1H-imidazo[4,5-c]quinoline-7-carboxylic acid (38) 
35 was suspended in EtOH with KOH. H2O2 was added and the reaction was stirred at reflux for 
4 h diluted with water, and acidified with 6 M HCl. The water layer was extracted 5x with DCM 
and evaporated to dryness. Crude product was purified by Combiflash (5%-10% MeOH in DCM) 
to obtain a white solid in 52% yield. 1H NMR (500 MHz, DMSO-d6) δ 14.43 (s, 1H), 8.37 (s, 1H), 
8.26 (s, 2H), 8.05 – 8.00 (d, J = 8.2 Hz, 1H), 7.68 (s, 1H), 4.82 (s, 2H), 4.56 (d, J = 7.6 Hz, 2H), 
3.61 (q, J = 6.9 Hz, 2H), 2.21 (dt, J = 14.0, 7.0 Hz, 1H), 1.17 (t, J = 7.0 Hz, 3H), 0.94 (d, J = 6.6 
Hz, 6H); 13C NMR (126 MHz, DMSO-d6) δ 167.02, 153.34, 150.29, 135.11, 134.35, 125.92, 
123.65, 122.60, 118.78, 114.89, 106.65, 66.21, 64.33, 52.63, 29.26, 19.67, 15.37. HRMS (m/z): 
[M-] calcd for C18H21N4O3, 341.1614; found 341.1628. 
 
Biology: 
NFκB-Inducible SEAP Reporter Assay for TLR-7 Activity: 
TLR-7/8 analog activities were assessed using HEK-Blue hTLR7 and Null1-k cell lines from 
InvivoGen. HEK-Blue hTLR7 cells are HEK293 cells co-transfected with the hTLR7 gene and an 
optimized secreted embryonic alkaline phosphatase (SEAP) reporter gene. HEK-Blue Null1-k 
cells are transfected with the SEAP reporter gene but do not express the hTLR7 gene and are 
used as a control. 
The experiments followed manufacturer protocol as follows: 
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SEAP levels were measured via absorbance at 637 nm using HEK-Blue Detection cell culture 
medium (InvivoGen), which contains an SEAP specific colorimetric substrate. Compound stock 
solutions were first diluted in sterile DMSO at a concentration of 100 M. Lower concentrations 
were prepared by serial dilution of the initial 100 M stock samples into sterile DMSO and these 
solutions (22 L) were subsequently diluted into sterile H2O (198 L) using a BioTek Precision 
XS instrument. HEK-Blue hTLR7 and Null1-k cell suspensions in sterile HEK-Blue Detection 
medium were prepared at a density of ~280,000 cells per mL. Corning 3603 clear bottom, 96-well 
tissue culture treated plates were seeded with hTLR7 and Null1-k cell suspensions (180 μL/well), 
after which 20μL of the various sample concentrations in 10% v/v DMSO/H2O were added (20 
μL) to yield the desired testing concentration in 1% v/v DMSO. The plate was incubated at 37 °C 
and 5% CO2 in the dark. Absorbance measurements were taken at 637 nm at 12 and 17-hour 
time points, 4 replicates per concentration point, per cell line (hTLR7, Null1-k). 
The positive control used was Imiquimod and Resiquimod at concentrations of 0.02 μM, 0.2 μM, 
2 μM, 20 μM, and 50 μM. The negative control (or vehicle control) used was water. Compounds 
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